scholarly journals Nucleolin-Targeting AS1411 Aptamer-Modified Micelle for the Co-Delivery of Doxorubicin and miR-519c to Improve the Therapeutic Efficacy in Hepatocellular Carcinoma Treatment

2021 ◽  
Vol Volume 16 ◽  
pp. 2569-2584
Author(s):  
Xiao Liang ◽  
Yudi Wang ◽  
Hui Shi ◽  
Mengmeng Dong ◽  
Haobo Han ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Therapeutic Efficacy ◽  
As1411 Aptamer

The long term therapeutic efficacy and the safety of percutaneous holmium injection for the treatment of small hepatocellular carcinoma

2003 ◽  
Vol 38 ◽  
pp. 6 ◽  
Author(s):  
J.K. Kim ◽  
K.H. Han ◽  
J.T. Lee ◽  
C.Y. Chon ◽  
Y.M. Moon ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Therapeutic Efficacy ◽  
Small Hepatocellular Carcinoma

scholarly journals Comparison of the Number of Image Acquisitions and Procedural Time Required for Transarterial Chemoembolization of Hepatocellular Carcinoma with and without Tumor-Feeder Detection Software

2013 ◽  
Vol 2013 ◽  
pp. 1-6 ◽  
Author(s):  
Jin Iwazawa ◽  
Shoichi Ohue ◽  
Naoko Hashimoto ◽  
Takashi Mitani
Keyword(s):  
Hepatocellular Carcinoma ◽  
Transarterial Chemoembolization ◽  
Therapeutic Efficacy ◽  
Single Session ◽  
Feeder Vessel ◽  
Vessel Detection ◽  
Procedural Time ◽  
The Mean ◽  
Detection Software ◽  
Time Required

Purpose. To compare the number of image acquisitions and procedural time required for transarterial chemoembolization (TACE) with and without tumor-feeder detection software in cases of hepatocellular carcinoma (HCC).Materials and Methods. We retrospectively reviewed 50 cases involving software-assisted TACE (September 2011–February 2013) and 84 cases involving TACE without software assistance (January 2010–August 2011). We compared the number of image acquisitions, the overall procedural time, and the therapeutic efficacy in both groups.Results. Angiography acquisition per session reduced from 6.6 times to 4.6 times with software assistance (P<0.001). Total image acquisition significantly decreased from 10.4 times to 8.7 times with software usage (P=0.004). The mean procedural time required for a single session with software-assisted TACE (103 min) was significantly lower than that for a session without software (116 min,P=0.021). For TACE with and without software usage, the complete (68% versus 63%, resp.) and objective (78% versus 80%, resp.) response rates did not differ significantly.Conclusion. In comparison with software-unassisted TACE, automated feeder-vessel detection software-assisted TACE for HCC involved fewer image acquisitions and could be completed faster while maintaining a comparable treatment response.

Percutaneous cryoablation for perivascular hepatocellular carcinoma: Therapeutic efficacy and vascular complications

2018 ◽  
Vol 29 (2) ◽  
pp. 654-662 ◽  
Author(s):  
Ran Kim ◽  
Tae Wook Kang ◽  
Dong Ik Cha ◽  
Kyoung Doo Song ◽  
Min Woo Lee ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Therapeutic Efficacy ◽  
Vascular Complications ◽  
Percutaneous Cryoablation

Therapeutic Efficacy of Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma

1995 ◽  
Vol 19 (2) ◽  
pp. 198-203 ◽  
Author(s):  
Katsuyoshi Ito ◽  
Kazumitsu Honjo ◽  
Takeshi Fujita ◽  
Mihoko Matsui ◽  
Hitomi Awaya ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Therapeutic Efficacy ◽  
Transcatheter Arterial Chemoembolization ◽  
Arterial Chemoembolization

Therapeutic efficacy of improved α-fetoprotein promoter-mediated tBid delivered by folate-PEI600-cyclodextrin nanopolymer vector in hepatocellular carcinoma

2014 ◽  
Vol 324 (2) ◽  
pp. 183-191 ◽  
Author(s):  
Bao-guang Hu ◽  
Li-ping Liu ◽  
George G. Chen ◽  
Cai Guo Ye ◽  
Kevin K.C. Leung ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Therapeutic Efficacy

Radiofrequency Ablation of Hepatocellular Carcinoma in Patients with Decompensated Cirrhosis: Evaluation of Therapeutic Efficacy and Safety

2006 ◽  
Vol 186 (5_supplement) ◽  
pp. S261-S268 ◽  
Author(s):  
Young Kon Kim ◽  
Chong Soo Kim ◽  
Gyong Ho Chung ◽  
Young Min Han ◽  
Sang Yong Lee ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Radiofrequency Ablation ◽  
Therapeutic Efficacy ◽  
Decompensated Cirrhosis ◽  
Efficacy And Safety

Mutation profiles in circulating tumor DNA (ctDNA) to predict the efficacy of sorafenib treatment in patients with advanced hepatocellular carcinoma (HCC).

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e15648-e15648
Author(s):  
Ping Yang ◽  
Guanghui Ji ◽  
Qionghui Jiang ◽  
Zejun Lu ◽  
Yao Yu ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Gene Mutation ◽  
Therapeutic Efficacy ◽  
Genomic Dna ◽  
Mutation Frequency ◽  
Advanced Hepatocellular Carcinoma ◽  
Sequencing Analysis ◽  
Wild Type ◽  
Blood Samples ◽  
Mutation Type

e15648 Background: To find biomarkers from blood samples through ctDNA and leucocyte genomic DNA sequencing to predict the efficacy of sorafenib. Methods: CtDNA and leucocyte genomic DNA were extracted from patients with advanced hepatocellular carcinoma for sequencing analysis before and after targeted therapy with sorafenib. Mutation profiles were obtained by deep sequencing of 620 selected genes for further bioinformatics analysis. Gene mutation frequency and status were further integrated with clinical data to dynamically monitor and predict the efficacy of sorafenib. Results: Twelve patients with advanced hepatocellular carcinoma admitted to our hospital from March 2017 to September 2018 were enrolled. A total of 27 blood samples were collected for further analysis. The results showed that there were significant differences in BRD4 and FANCG gene mutation abundance between therapeutic effect group and poor effect group (p = 0.014). The mutations of BRD4, FANCG and TP53 were associated with shorter PFS (BRD4 mutation type vs wild type: 12 weeks vs 32 weeks, p = 0.0011; FANCG mutation type vs wild type: 16 weeks vs 32 weeks, p = 0.0103; TP53 mutation type vs wild type: 8 weeks vs 32 weeks, p = 0.0095). Furthermore, we found another 19 genes (SDHA, OTUD7A, TMPRSS2, NAV3, AKT1, EIF2S2, DICER1, MAP3K1, RAD9A, TCF3, IRS1, PIK3C2G, CTCF, TSHZ2, ITPKB, KDM5C, STAG2, AMER1, CDC27) associated with therapeutic efficacy, and dynamic changes of these 19 genes mutation alleys could predict therapeutic efficacy. Conclusions: Our results showed that mutations in ctDNA could predict the efficacy and prognosis of sorafenib for advanced hepatocellular carcinoma, and that dynamic monitoring of mutation frequency in ctDNA of peripheral blood samples could be an additional method to monitor therapeutic efficacy of sorafenib. The clinical significance of the mutations of BRD4, FANCG, TP53 and another 19 genes we found needs to be confirmed on a larger scale.

Sign in / Sign up

Export Citation Format

Share Document